Pressmeddelande -
Bengt Å Johansson takes role as acting CEO of Dilafor
”Under Anders management, Dilafor has successfully concluded a clinical Phase II study for the treatment of dystocia/protracted labor, and a clinical Phase I study for the treatment of severe malaria where the planning for Phase II trials is ongoing. Now we will search for Anders replacement, and for this process as for the continued development of Dilafor we are happy to have him still serving the company as board member”, says Bengt Å Johansson, chairman of the board.
For further information, please contact:
Bengt Å Johansson, Chairman of the Board, Dilafor AB
Tel: +46-706-80 47 62, e-mail: bengt.johansson@dilafor.com
Kategorier
- dilafor
TO THE EDITORS
About Dilafor
Dilafor AB is a Swedish R&D company focused on developing pharmaceutical products with low anticoagulant activity from heparin. The company has a balanced product portfolio with two projects in clinical development phase, tafoxiparin for the prevention and treatment of dystocia/protracted labor and sevuparin for the treatment of severe malaria. Dilafor is part of Karolinska Development.
